A Multicomponent Skin-Targeted COVID-19 Vaccine Elicits Robust Humoral and Cellular Immune Responses

    Stephen C. Balmert, Z. G. Ghozloujeh, Cate Carey, Tina L. Sumpter, G. Erdö́s, Emrullah Korkmaz, Louis D. Falo
    Image of study
    TLDR The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
    The document reports on a study of a new skin-targeted COVID-19 vaccine delivered via microarray patches (MAPs) that produced strong antibody and cellular immune responses in mice. The vaccine, which includes a recombinant SARS-CoV-2 protein antigen and sometimes an immune stimulant, was more effective in generating key immune responses, such as Th1 and IgG2c, than traditional intramuscular injections. Additionally, the vaccine showed promise in human skin studies, eliciting enhanced activation of dendritic cells. The MAPs' ease of use, stability, and strong immunogenicity suggest they could improve vaccination strategies and aid in controlling the spread of SARS-CoV-2 and other diseases.
    Discuss this study in the Community →